

Fiscal Impact Statement

91st General Assembly of the State of Arkansas
Regular Session, 2017

DATE: 02/24/2017
BILL: HB1592, As originally introduced
SPONSOR: Leding

SUBTITLE:

TO PROVIDE PARITY IN HEALTH BENEFIT PLAN COVERAGE BETWEEN ORALLY ADMINISTERED ANTICANCER MEDICATION AND INTRAVENOUSLY ADMINISTERED ANTICANCER MEDICATION.

TOPIC

√ Benefit Parity

AFFECTED FUNDS

REVENUE IMPACT

√ \$0 *

ASSUMPTIONS - BASED ON:

√ * Future impact on insurance premiums.

ADDITIONAL COMMENTS

√ * No impact to Medicaid (state).

Prepared by Richard Wilson; Office of Research Services, AR Bureau of Legislative Research

Approved by: _____